Stay updated on Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial
Sign up to get notified when there's something new on the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page.

Latest updates to the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a new site revision tag 'Revision: v3.4.2' and removal/update of prior system notices (including a government funding/operating status notice and 'Revision: v3.4.1'). These are administrative updates and do not modify study content or its presentation.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a clinical study report synopsis, sponsor information (AbbVie), Helpful Links, and a site revision note (Revision: v3.4.1). Removed the previous revision (Revision: v3.4.0) and included a government funding notice for currency of information.SummaryDifference0.6%

- Check28 days agoChange DetectedAdded a glossary toggle and new metadata labels 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check42 days agoChange DetectedMinor update: the page revision changed from v3.3.3 to v3.3.4; no other content or functionality appear to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedExpanded and reorganized the Locations section to include prefecture-level locations (Aichi-ken, Chiba, Hokkaido, Mie-ken, Osaka, Shizuoka, Tokyo), with a revision note indicating v3.3.3.SummaryDifference0.8%

- Check92 days agoChange DetectedPublications are now described as automatically filled from PubMed and may not all relate to the study. The revision label changed from v3.2.0 to v3.3.2 and certain publication-related items (e.g., 'clinical study report synopsis', 'AbbVie', 'Helpful Links Provided by') were removed.SummaryDifference0.3%

Stay in the know with updates to Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page.